Related references
Note: Only part of the references are listed.Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
Yagiz Uresin et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2007)
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY
A. Recio-Mayoral et al.
CARDIOVASCULAR DRUGS AND THERAPY (2007)
Letter by Testa et al regarding article, Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization
Luca Testa et al.
CIRCULATION (2007)
Letter by Fisher and Johns regarding article, variable platelet response to aspirin and clopidogrel in atherothrombotic disease
Matt Fisher et al.
CIRCULATION (2007)
Novel 2,7-dialkyl-substituted 5(S)-Amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin
Richard Goeschke et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Structural modification of the P2′ position of 2,7-dialkyl-substituted 5(S)-Amino-4(S)-hydroxy-8-phenyl-octanecarboxamides:: The discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets
Juergen Maibaum et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers
Felix Waldmeier et al.
DRUG METABOLISM AND DISPOSITION (2007)
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
Suzanne Oparil et al.
LANCET (2007)
Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness
Jean E. Sealey et al.
AMERICAN JOURNAL OF HYPERTENSION (2007)
Direct renin inhibition with aliskiren in obese patients with arterial hypertension
Jens Jordan et al.
HYPERTENSION (2007)
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects
Sujata Vaidyanathan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment
Sujato Vaidyanathan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker
Eoin O'Brien et al.
HYPERTENSION (2007)
Renin inhibition with aliskiren provides additive anti hypertensive efficacy when used in combination with hydrochlorothiazide
Alberto Villamil et al.
JOURNAL OF HYPERTENSION (2007)
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment
Sujata Vaidyanathan et al.
CLINICAL PHARMACOKINETICS (2007)
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
Sujata Vaidyanathan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension
Toshio Kushiro et al.
HYPERTENSION RESEARCH (2006)
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers
S. Vaidyanathan et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
ESH-ESC guidelines for the management of hypertension
Serap Erdine et al.
HERZ (2006)
Direct renin inhibition with aliskiren in hypertension and target organ damage
Dominik N. Mueller et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus
Charlie Zhao et al.
CLINICAL PHARMACOKINETICS (2006)
Complement activation in angiotensin II - Induced organ damage
E Shagdarsuren et al.
CIRCULATION RESEARCH (2005)
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats
B Pilz et al.
HYPERTENSION (2005)
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
AH Gradman et al.
CIRCULATION (2005)
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats
JM Wood et al.
JOURNAL OF HYPERTENSION (2005)
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
B Williams et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the handle'' region for nonproteolytic activation of prorenin
A Ichihara et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Prevalence of hypertension, its awareness and control in adult population in Japan
A Sekikawa et al.
JOURNAL OF HUMAN HYPERTENSION (2004)
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
M Azizi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists
M Azizi et al.
CIRCULATION (2004)
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
P Bramlage et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Structure-based design of aliskiren, a novel orally effective renin inhibitor
JM Wood et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure - The JNC 7 Report
AV Chobanian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
A Stanton et al.
HYPERTENSION (2003)
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin
G Nguyen et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100) - Comparison with enalapril
J Nussberger et al.
HYPERTENSION (2002)
Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study
A Hozawa et al.
HYPERTENSION RESEARCH (2002)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Mast cell chymase expression and mast cell phenotypes in human rejected kidneys
M Yamada et al.
KIDNEY INTERNATIONAL (2001)
Angiotensin II-generating enzymes
LA Belova
BIOCHEMISTRY-MOSCOW (2000)
Structure-based drug design:: the discovery of novel nonpeptide orally active inhibitors of human renin
J Rahuel et al.
CHEMISTRY & BIOLOGY (2000)
Blood pressure-independent effects in rats with human renin and angiotensinogen genes
E Mervaala et al.
HYPERTENSION (2000)
Share Paper
